The downgrade from Overweight to Equal-Weight by Morgan Stanley indicates a less optimistic outlook for Ventyx Biosciences. The significant reduction in the price target from $46 to $6 suggests that the analyst sees less upside potential in the stock, which could negatively impact its short-term price.